[HTML][HTML] A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19
The emergence of coronavirus disease 2019 (COVID-19), caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected many countries throughout …
respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected many countries throughout …
[HTML][HTML] Non-steroidal anti-inflammatory drugs in the era of the Covid-19 pandemic in the context of the human and the environment
D Wojcieszyńska, H Guzik, U Guzik - Science of the Total Environment, 2022 - Elsevier
From 2019, life in the world has mainly been determined by successive waves of the COVID-
19 epidemic. During this time, the virus structure, action, short-and long-term effects of the …
19 epidemic. During this time, the virus structure, action, short-and long-term effects of the …
[HTML][HTML] Nigella sativa for the treatment of COVID-19: An open-label randomized controlled clinical trial
AE Koshak, EA Koshak, AF Mobeireek… - … Therapies in Medicine, 2021 - Elsevier
Abstract Background Effective treatment for Coronavirus Disease-2019 (COVID-19) is under
intensive research. Nigella sativa oil (NSO) is a herbal medicine with antiviral and …
intensive research. Nigella sativa oil (NSO) is a herbal medicine with antiviral and …
Development and validation of a sensitive, fast and simple LC-MS/MS method for the quantitation of favipiravir in human serum
Favipiravir is a broad-spectrum inhibitor of viral RNA polymerase. It is currently used as a
possible treatment for coronavirus disease 2019 (COVID-19). Pre-clinical or clinical trials of …
possible treatment for coronavirus disease 2019 (COVID-19). Pre-clinical or clinical trials of …
Systematic review and meta-analysis of cell therapy for COVID-19: global clinical trial landscape, published safety/efficacy outcomes, cell product manufacturing and …
PS Couto, N Al-Arawe, IS Filgueiras… - Frontiers in …, 2023 - frontiersin.org
During the pandemic of severe respiratory distress syndrome coronavirus 2 (SARS-CoV2),
many novel therapeutic modalities to treat Coronavirus 2019 induced disease (COVID-19) …
many novel therapeutic modalities to treat Coronavirus 2019 induced disease (COVID-19) …
Integrated bioinformatics–cheminformatics approach toward locating pseudo‐potential antiviral marine alkaloids against SARS‐CoV‐2‐Mpro
The emergence of the severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)
with the most contagious variants, alpha (B. 1.1. 7), beta (B. 1.351), delta (B. 1.617. 2), and …
with the most contagious variants, alpha (B. 1.1. 7), beta (B. 1.351), delta (B. 1.617. 2), and …
Systematic review: cystic fibrosis in the SARS-CoV-2/COVID-19 pandemic
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and
the development of life-threatening COVID-19 are believed to disproportionately affect …
the development of life-threatening COVID-19 are believed to disproportionately affect …
COVID-19 and dentistry in 72 questions: An overview of the literature
The outbreak of Coronavirus Disease 2019 (COVID-19), caused by Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has significantly affected the dental …
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has significantly affected the dental …
Molecular docking and dynamics studies of curcumin with COVID-19 proteins
Abstract Coronavirus disease 2019 (COVID-19) is caused by a Severe Acute Respiratory
Syndrome-Coronavirus 2 (SARS-CoV-2), which is a positive-strand RNA virus. The SARS …
Syndrome-Coronavirus 2 (SARS-CoV-2), which is a positive-strand RNA virus. The SARS …
Computationally prioritized drugs inhibit SARS-CoV-2 infection and syncytia formation
The pharmacological arsenal against the COVID-19 pandemic is largely based on generic
anti-inflammatory strategies or poorly scalable solutions. Moreover, as the ongoing …
anti-inflammatory strategies or poorly scalable solutions. Moreover, as the ongoing …